ABOUT DATAMONITOR HEALTHCARE 2
About the Immunology & Inflammation pharmaceutical analysis team 2
CHAPTER 1 EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the disease market 4
Related reports 6
Upcoming related reports 6
CHAPTER 2 MARKET DEFINITION 8
The inflammatory bowel disease market definition 8
Biologics 8
TNF inhibitors 8
Integrin inhibitor 9
Intestinal anti-inflammatory drugs (5-aminosalicylates) 9
Immunomodulators 10
Corticosteroids 11
ICD-10 codes used to define the inflammatory bowel disease indications 11
Crohn's disease 12
Ulcerative colitis 12
Assumptions and caveats for diagnosis value estimates 13
Diagnosis value based on retail data only 13
CHAPTER 3 PATIENT ACQUISITION PROCESS 15
Introduction 15
Patient care path 15
Points of influence in the patient care path 15
Trigger Point 1: Disease awareness among patients and physicians is critical to increasing diagnosis rates 17
Trigger Point 2: Tackling patient compliance during maintenance treatment 19
Trigger Point 3: Physician assessment of disease severity influences treatment choice - using "step-up" or "top-down" strategies 20
Factors that influence patient flow through the healthcare system 21
Increased public awareness leading to early presentation to PCP or a specialist 22
Symptoms of disease can be mild, therefore, patients do not present for treatment 22
Patients sometimes forget to take medication if they feel symptoms have improved 23
Self-management limits patient follow-up 23
CHAPTER 4 MARKET OVERVIEW 24
Seven major markets 24
Current market assessment 24
Impressive historical growth in inflammatory bowel disease sales from 2004 to 2007 24
Inflammatory bowel disease market volume is increasing, but due to the uptake of biologics, sales growth is outstripping it 27
Anti-TNFs contributed to half of all sales in the inflammatory bowel disease market in 2007 29
Spain and France show highest growth in the seven major markets in 2006-07 31
Future market assessment 32
Opportunities and threats 41
Opportunities 41
Threats 46
US 49
Current market assessment 49
The US was the largest of the seven major markets in 2007 49
Anti-TNFs held a 55% share of the US inflammatory bowel disease market in 2007 50
Corticosteroids demonstrated highest CAGR from 2004 to 2007 51
Abbott's Humira experienced strong US uptake from 2006 to 2007 52
Rowasa's US sales continue to decrease in light of generic competition 53
Future market assessment 54
Opportunities and threats 59
Opportunities 59
Threats 59
Japan 61
Current market assessment 61
Japan was the second largest market in terms of sales in 2007 61
Intestinal anti-inflammatory drug class dominates inflammatory bowel disease market in Japan 62
Nisshin Kyorin's Pentasa is the leading brand for inflammatory bowel disease in Japan 63
Mitsubishi Tanabe's Remicade experiences low growth from 2006 to 2007 64
Future market assessment 65
Opportunities and threats 69
Opportunities 69
Threats 71
Europe 73
Current market assessment 73
Inflammatory bowel disease sales grew by 28% in the 5EU from 2006 to 2007 73
Anti-TNFs drive growth in the 5EU inflammatory bowel disease market 74
Intestinal anti-inflammatory drug class sales remain ahead of anti-TNFs in 5EU 75
Remicade demonstrated the best performance in the 5EU from 2006 to 2007 75
Future market assessment 76
Opportunities and threats 81
Opportunities 81
Threats 82
France 84
Current market assessment 84
Inflammatory bowel disease market achieved sales of $137m in 2007 84
Future market assessment 85
Germany 90
Current market assessment 90
Germany is the largest inflammatory bowel disease market in the 5EU 90
Future market assessment 91
Italy 96
Current market assessment 96
Second smallest inflammatory bowel disease market behind Spain in 2007 96
Future market assessment 97
Spain 102
Current market assessment 102
Spain showed highest CAGR of all the major markets from 2004 to 2007 102
Future market assessment 103
UK 108
Current market assessment 108
Although anti-TNF class is growing rapidly, intestinal anti-inflammatory agents retain largest share of the UK market 108
Future market assessment 109
Rest of World snapshot 114
Current market assessment 114
Rest of World accounts for only 13% of global inflammatory bowel disease market sales 115
Global inflammatory bowel disease market sales increased with a 14.3% CAGR from 2004 to 2007 115
Asia-Pacific, particularly China, is the area of highest growth in the Rest of World 117
Other regions, such as Russia, show promising growth in the inflammatory bowel disease market 119
Canada is the largest Rest of World market after the rest of Europe. 120
Remicade is the leading brand in the Rest of World 121
Opportunities and threats 122
Opportunities 122
Threats 123
CHAPTER 5 BRAND DYNAMICS 125
Overview of competitive landscape 125
Drivers of brand choice 126
Factors driving brand choice in the anti-TNF class 128
Patient preference, cost and mode of delivery are among drivers of brand choice for anti-TNFs 128
US formulary status for leading brands 129
Humira is better positioned than Remicade in most US formularies 130
Asacol has desirable Tier-2 coverage in most plans 131
Remicade (infliximab; Centocor/Johnson & Johnson, Schering-Plough and Mitsubishi Tanabe) 131
Drug profile 132
Product positioning 133
Remicade is positioned in multiple Crohn's disease patient populations 133
Ulcerative colitis approval expands scope for Remicade product positioning 134
Colectomy avoidance indication will have a small positive impact on Remicade sales 135
Remicade advances up to second-line therapy for Crohn's disease in the EU 136
SONIC trial directly evaluates Remicade against immunosuppressants 136
Marketing mix 137
Marketing mix for Remicade is varied, but Centocor is promoting the message of evidence and experience 137
Centocor finds new marketing channel in the form of a documentary 138
Mitsubishi Tanabe's strengthened promotion of Remicade in Japan is a core marketing strategy 139
Brand forecast to 2017 140
Remicade's sales grow in the near term but then decline amid competition from new products and biosimilars 140
Japan is the only major market where Remicade will experience overall growth to 2017 142
Infliximab biosimilars will achieve sales of $160m in 2017 145
Strategic recommendations 146
Humira (adalimumab; Abbott, Eisai) 146
Drug profile 147
Product positioning 148
The GAIN trial positioned Humira to capture infliximab-failure patients, however, competition now comes from Cimzia and Tysabri 148
Abbott now has 2-year data for Humira, which will allow better positioning against Remicade 148
Humira is building up clinical data beyond remission 149
Remicade will remain choice ahead of Humira for treating fistulizing Crohn's disease 150
Marketing mix 150
Abbott has relied on heavy marketing of Humira 150
Abbott signs up Eisai to co-promote Humira in Japan 152
Abbott promoted the "sustainable impact" of Humira at the DDW 2008 152
Brand forecast to 2017 153
Humira will experience strong uptake for inflammatory bowel disease in the seven major markets and will be market leader by 2014 153
Strategic recommendations 157
Cimzia (certolizumab; UCB) 157
Drug profile 159
Product positioning 160
UCB chose a lower price point to position Cimzia in the competitive anti-TNF market 160
Like Humira, Cimzia will be positioned in the infliximab-failure population, but as third-line choice 160
Marketing mix 161
UCB must launch a hard-hitting marketing campaign for Cimzia 161
'CIMplicity' includes the home health nurse program for Cimzia administration 161
Crohn's & Me society will increase disease awareness and promote Cimzia 162
UCB and Otsuka will co-promote Cimzia in Japan 163
Brand forecast to 2017 163
Third-line competition will cap Cimzia sales in inflammatory bowel disease 163
Strategic recommendations 166
Tysabri (natalizumab; Biogen Idec, Elan) 166
Drug profile 168
Product positioning 169
Tysabri positioned towards Crohn's disease patients who fail anti-TNF therapy 169
Tysabri reduces hospitalization rates 169
Elan and Biogen Idec funded study shows Tysabri most cost-effective therapy for anti-TNF-failure patients 170
Marketing mix 170
TOUCH program - newly confirmed cases of PML will limit uptake of Tysabri in Crohn's disease 171
Brand forecast to 2017 172
Safety concerns dampen Tysabri's sales forecast in Crohn's disease 172
Strategic recommendations 174
Asacol (mesalazine, Procter & Gamble) 175
Drug profile 175
Product positioning 176
Procter & Gamble's strong product positioning facilitates Asacol's market leadership 176
Asacol looking to compete with Pentasa in Japan 177
Marketing mix 177
Asacol is the most heavily promoted intestinal anti-inflammatory brand, but Lialda is close behind 177
Brand forecast to 2017 178
Competition from Lialda and Salofalk Granustix will diminish Asacol's US and 5EU sales 178
Strategic recommendations 181
Pentasa (mesalazine; Shire, Ferring, Nisshin Kyorin) 182
Drug profile 182
Product positioning 183
Pentasa has ulcerative colitis indication, but Crohn's disease generates majority of sales, especially in the US 183
Pentasa and Lialda co-exist in Shire's gastroenterology franchise without signs of cannibalization 184
Once-daily Pentasa more effective than twice-daily dosing of Pentasa 185
Marketing mix 185
Pentasa's promotional spend falls behind Asacol and Lialda 185
Brand forecast to 2017 186
Strategic recommendations 188
Lialda/Mezavant (MMX mesalazine; Shire, Giuliani, Cosmo) 189
Target product profile 189
Product positioning 190
Shire will roll-out Lialda across the rest of the EU in 2008 190
Shire markets Lialda as a once-daily tablet in the US, but reduced number of tablets per day does not equate to lower costs 190
Lialda aims to acquire share from market-leader Asacol 191
Marketing mix 192
Shire and Takeda will co-promote Lialda in the US 192
Drug forecast to 2017 193
Once-daily dosing and reduced pill burden will propel Lialda to become the market-leading 5-ASA brand 193
Strategic recommendations 197
Golimumab (CNTO-148; Centocor/Johnson & Johnson, Schering-Plough, Mitsubishi Tanabe, Janssen Pharmaceutical) 197
Target product profile 198
Development overview 199
Product positioning 200
Centocor/Johnson & Johnson and Schering-Plough will position golimumab (CNTO-148) in the ulcerative colitis population 200
Marketing mix 201
Golimumab's (CNTO-148) marketing will be akin to Remicade's 201
Drug forecast to 2017 201
Strategic recommendations 203
Other marketed brands 204
Salofalk Granustix (mesalazine; Dr Falk Pharma, Salix Pharmaceuticals) 204
Salofalk Granustix is a once-daily granule mesalazine formulation and will compete with Lialda in the US 205
Salix Pharmaceuticals's experienced sales force an advantage to Salofalk Granustix 206
Entocort (budesonide; Prometheus Laboratories, AstraZeneca) 207
Entocort patent challenges could result in early generic equivalents in the US 207
Colazal (balsalazide; Salix Pharmaceuticals) 208
Colazal set for significant generic erosion in the US 208
Salix aiming to launch a 1,100mg formulation of Colazal in the US 209
Other promising late-stage pipeline agents 210
CCX-282 (Traficet-EN; ChemoCentryx, GlaxoSmithKline) 211
Ustekinumab (CNT0-1275; Centocor/Johnson & Johnson, Janssen-Cilag) 214
MMX budesonide 217
Orencia (abatacept) 218
CHAPTER 6 KEY DEVELOPERS 220
Strategic overview 220
Trends in corporate strategy 221
Key companies with a biologic have a single marketed drug for inflammatory bowel disease 221
Collaboration, licensing arrangements and acquisition are the main strategic trends in the inflammatory bowel disease market 222
Centocor/Johnson & Johnson 223
Corporate strategy 223
Remicade is the only marketed drug in Centocor/Johnson & Johnson's immunology portfolio 223
Inflammatory bowel disease portfolio assessment 224
Abbott 226
Corporate strategy 226
Humira is at the core of Abbott's business and is the only product in its immunology franchise 226
Inflammatory bowel disease portfolio assessment 227
Portfolio assessment of other leading companies 228
Schering-Plough 228
Salix 228
Prometheus 228
Shire 229
BIBLIOGRAPHY 231
Journal papers 231
Websites 236
Publications 242
Datamonitor reports 242
APPENDIX A - MARKET ASSUMPTIONS 243
New product launches 243
Patent expiries 244
Brand erosion 244
US brand erosion: Rowasa case study 244
Patent expiry dates summary 244
Data definitions, limitations and assumptions 245
Standard units 245
Japanese market data 245
Derivation of sales forecasts and pricing trends 245
Forecast methodology 246
APPENDIX B 247
Contributing experts 247
Report methodology 247
About Datamonitor 248
About Datamonitor Healthcare 248
About the Immunology & Inflammation analysis team 249
Disclaimer 250
List of Tables
Table 1: Datamonitor's definition of Crohn's disease 12
Table 2: Datamonitor's definition of ulcerative colitis 13
Table 3: Gastroenterologist breakdown by region for IMS Prescribing Insight data, 2007 14
Table 4: Key factors influencing patient flow through the healthcare system 22
Table 5: Inflammatory bowel disease-specific volume sales (million standard units) split by drug class in the seven major markets, 2004-07 29
Table 6: Sales forecasts for inflammatory bowel disease in the seven major markets ($m), 2007-2017 36
Table 7: Estimated number of patients with Crohn's disease and ulcerative colitis who are undiagnosed in the seven major markets, 2007 45
Table 8: Patent expiry dates and level of biosimilar risk for the biologic brands for inflammatory bowel disease, 2008-2017 48
Table 9: Summary of opportunities and threats in the inflammatory bowel disease market across the seven major markets, 2008 49
Table 10: US sales and growth of drug classes and brands in the inflammatory bowel disease market, 2007 50
Table 11: Sales forecasts for the inflammatory bowel disease market in the US ($m), 2007-2017 57
Table 12: Summary of opportunities and threats in the inflammatory bowel disease market in the US, 2007 61
Table 13: Sales and growth of drug classes and brands in the inflammatory bowel disease market in Japan, 2007 62
Table 14: Sales forecasts for the inflammatory bowel disease market in Japan ($m), 2007-2017 68
Table 15: Summary of opportunities and threats in the inflammatory bowel disease market in Japan, 2007 73
Table 16: Sales and growth of drug classes in the 5EU inflammatory bowel disease market, 2007 73
Table 17: Sales forecasts for the inflammatory bowel disease market in the 5EU ($m), 2007-2017 79
Table 18: Summary of opportunities and threats in the European market, 2008 84
Table 19: Sales forecasts for inflammatory bowel disease market in France ($m), 2007-2017 88
Table 20: Sales forecasts for inflammatory bowel disease market in Germany ($m), 2007-2017 94
Table 21: Sales forecasts for the inflammatory bowel disease market in Italy ($m), 2007-2017 100
Table 22: Sales forecasts for the inflammatory bowel disease market in Spain ($m), 2007-2017 106
Table 23: Sales forecasts in the inflammatory bowel disease market in the UK ($m), 2007-2017 112
Table 24: Annual global sales in the inflammatory bowel disease market split by region ($m), 2004-07 117
Table 25: Comparison of leading branded drug sales for inflammatory bowel disease in the seven major markets (7MM) and the Rest of World (ROW) ($m), 2007 122
Table 26: Leading branded drug sales for inflammatory bowel disease in the seven major markets ($m), 2007-2017 126
Table 27: Predictors of strong preference for subcutaneous and intravenous anti-TNF formulations 129
Table 28: Formulary status in the US for leading brands in inflammatory bowel disease, 2008 130
Table 29: Remicade (infliximab) - drug profile, 2008 132
Table 30: Approvals for Remicade in Crohn's disease populations in the seven major markets, 1998-2007 133
Table 31: Sales forecast for Remicade (infliximab) for inflammatory bowel disease in the seven major markets ($m), 2007-2017 141
Table 32: Key factors impacting sales of Remicade, 2007-2017 144
Table 33: Humira (adalimumab) - drug profile, 2008 147
Table 34: Humira sales in inflammatory bowel disease by country in the seven major markets ($m), 2007-2017 154
Table 35: Key factors impacting sales of Humira, 2007-2017 156
Table 36: Cimzia (certolizumab) - drug profile, 2008 159
Table 37: Comparison of the annual cost per patient of anti-TNF agents in the US, 2008 160
Table 38: Key factors impacting sales of Cimzia, 2007-2017 165
Table 39: Tysabri (natalizumab) - drug profile, 2008 168
Table 40: Key factors impacting sales of Tysabri, 2007-2017 174
Table 41: Asacol (mesalazine) - drug profile, 2008 175
Table 42: Asacol (mesalamine) sales for inflammatory bowel disease in US, Japan, Italy and the UK ($m), 2007-2017 180
Table 43: Pentasa (mesalazine) - drug profile, 2008 182
Table 44: Pentasa (mesalamine) sales for inflammatory bowel disease in the seven major markets ($m), 2007-2017 187
Table 45: Lialda - target product profile, 2008 189
Table 46: Cost analysis for Lialda, Asacol and Pentasa in the US, 2007 191
Table 47: Lialda (MMX mesalazine) sales for inflammatory bowel disease in the US and 5EU ($m) , 2007-2017 195
Table 48: Key factors impacting sales of Lialda, 2007-2017 196
Table 49: Golimumab - target product profile, 2008 198
Table 50: Phase III clinical trial summary for golimumab (CNTO148) in ulcerative colitis, 2008 200
Table 51: Golimumab (CNTO-148) sales in ulcerative colitis in the US and 5EU, split by country ($m), 2007-2017 202
Table 52: Key factors impacting sales of Golimumab (CNTO-148), 2007-2017 203
Table 53: Other promising late-stage pipeline products for inflammatory bowel disease, 2008 211
Table 54: Clinical trial summary for CCX-282 in Crohn's disease, 2008 212
Table 55: Leading companies in the seven major markets inflammatory bowel disease market, 2007-2017 220
Table 56: Summary of licensing deals for major inflammatory bowel disease players, 2008 221
Table 57: Centocor portfolio assessment of inflammatory bowel disease agents, 2008 225
Table 58: Abbott portfolio assessment of inflammatory bowel disease agents, 2008 227
Table 59: Portfolio analysis of other key players in the inflammatory bowel disease market, 2008 230
Table 60: Datamonitor's launch dates for inflammatory bowel disease products in the US, 5EU and Japan, 2007-2017 243
Table 61: Patent expiry dates for the approved inflammatory bowel disease drugs in the seven major markets, 2008-2017 245
List of Figures
Figure 1: Crohn's disease patient care path 16
Figure 2: Ulcerative colitis patient care path 17
Figure 3: Inflammatory bowel disease-specific sales in the seven major markets by region ($m), 2004-07 25
Figure 4: Key events impacting the inflammatory bowel disease market, 2004-08 27
Figure 5: Inflammatory bowel disease-specific volume sales (million standard units) in the seven major markets by region, 2004-07 28
Figure 6: Inflammatory bowel disease-specific sales split by drug class in the seven major markets ($m), 2004-07 30
Figure 7: Inflammatory bowel disease market share in the seven major markets by drug class, 2004-07 31
Figure 8: Sales performance of the seven major inflammatory bowel disease markets by country, 2006-07 32
Figure 9: Sales forecasts for inflammatory bowel disease in the seven major markets ($m), 2007-2017 33
Figure 10: Sales forecasts for Crohn's disease and ulcerative colitis in the seven major markets ($m), 2007-2017 35
Figure 11: Total seven major market forecast sales and market share of inflammatory bowel disease drug classes ($m), 2017 39
Figure 12: Impact of key events on the inflammatory bowel disease market, 2007-2017 40
Figure 13: Step-up vs. top-down 43
Figure 14: Inflammatory bowel disease-specific sales split by class in the US ($m), 2004-07 51
Figure 15: Performance of the inflammatory bowel disease therapies in the US ($m), 2006-07 53
Figure 16: Sales forecasts for inflammatory bowel disease in the US ($m), 2007-2017 55
Figure 17: US forecast sales and market share of inflammatory bowel disease drug classes, 2017 56
Figure 18: Inflammatory bowel disease-specific sales split by class in Japan ($m), 2004-07 63
Figure 19: Performance of the inflammatory bowel disease therapies in Japan, 2006-07 64
Figure 20: Sales forecasts for inflammatory bowel disease in Japan ($m), 2007-2017 66
Figure 21: Japan forecast sales and market share of inflammatory bowel disease drug classes, 2017 67
Figure 22: Actual and projected annual Crohn's disease prevalence in Japan 1986-2018 70
Figure 23: 5EU inflammatory bowel disease-specific sales split by country ($m), 2004-07 74
Figure 24: Inflammatory bowel disease-specific sales in the 5EU markets split by drug class ($m), 2004-07 75
Figure 25: Performance of the inflammatory bowel disease therapies in the 5EU, 2006-07 76
Figure 26: Sales forecasts for inflammatory bowel disease market in the 5EU ($m), 2007-2017 77
Figure 27: 5EU forecast sales and market share of inflammatory bowel disease drug classes, 2017 78
Figure 28: Inflammatory bowel disease-specific sales split by class in France ($m), 2004-07 85
Figure 29: Sales forecasts for inflammatory bowel disease in France ($m), 2007-2017 86
Figure 30: France forecast sales and market share of inflammatory bowel disease drug classes, 2017 87
Figure 31: Inflammatory bowel disease-specific sales split by class in Germany ($m), 2004-07 91
Figure 32: Sales forecasts for inflammatory bowel disease in Germany ($m), 2007-2017 92
Figure 33: Germany forecast sales and market share of inflammatory bowel disease drug classes, 2017 93
Figure 34: Inflammatory bowel disease-specific sales split by class in Italy ($m), 2004-07 97
Figure 35: Sales forecasts for inflammatory bowel disease in Italy ($m), 2007-2017 98
Figure 36: Italy forecast sales and market share of inflammatory bowel disease drug classes, 2017 99
Figure 37: Inflammatory bowel disease-specific sales split by class in Spain ($m), 2004-07 103
Figure 38: Sales forecasts for inflammatory bowel disease in Spain ($m), 2007-2017 104
Figure 39: Spain forecast sales and market share of inflammatory bowel disease drug classes, 2017 105
Figure 40: Inflammatory bowel disease-specific sales split by class in the UK ($m), 2004-07 109
Figure 41: Sales forecasts for inflammatory bowel disease in the UK ($m), 2007-2017 110
Figure 42: UK forecast sales and market share of inflammatory bowel disease drug classes, 2017 111
Figure 43: Rest of World versus seven major market sales in the inflammatory bowel disease market ($m), 2007 115
Figure 44: Annual global sales in the inflammatory bowel disease market split by region, 2004-07 116
Figure 45: Annual Asia-Pacific sales in the inflammatory bowel disease market split by region, 2004-07 118
Figure 46: Inflammatory bowel disease market sales in Russia, South Africa and Egypt, 2004-07 120
Figure 47: Drivers of brand choice for inflammatory bowel disease, 2007 127
Figure 48: Promotional activity for Remicade by type as a percentage of total promotional spend in the seven major markets, 2005-07 138
Figure 49: Remicade sales in inflammatory bowel disease by country in the seven major markets ($m), 2007-2017 142
Figure 50: Remicade sales in Crohn's disease and ulcerative colitis in Japan ($m), 2007-2017 143
Figure 51: Remicade sales in Crohn's disease and ulcerative colitis in the seven major markets ($m), 2007-2017 144
Figure 52: Effect of biosimilars on the sales of Remicade (infliximab) for inflammatory bowel disease in the seven major markets ($m), 2007-2017 145
Figure 53: Promotional activity for Humira by type as a percentage (%) of total promotional spend in the seven major markets, 2005-07 152
Figure 54: Humira sales in inflammatory bowel disease by country in the seven major markets ($m), 2007-2017 155
Figure 55: Humira sales in Crohn's disease and ulcerative colitis in the seven major markets ($m), 2007-2017 156
Figure 56: Cimzia (certolizumab) sales for inflammatory bowel disease in the US ($m), 2007-2017 165
Figure 57: Tysabri (natalizumab) sales for inflammatory bowel disease in the US ($m), 2007-2017 173
Figure 58: Promotional activity for Asacol by type as a percentageof total promotional spend in the US, Italy and UK, 2005-07 178
Figure 59: Asacol (mesalamine) sales for inflammatory bowel disease in the US, Japan, Italy and the UK ($m), 2007-2017 180
Figure 60: Asacol (mesalamine) sales Crohn's disease and ulcerative colitis in Japan ($m), 2007-2017 181
Figure 61: Percentage of Pentasa's sales for each indication in the seven major markets, 2007 184
Figure 62: Sales of Pentasa and Lialda, as reported by Shire ($m), 2006-07 185
Figure 63: Promotional activity for Pentasa by type as a percentage (%) of total promotional spend in the major markets, 2005-07 186
Figure 64: Pentasa (mesalamine) sales for inflammatory bowel disease in the seven major markets ($m), 2007-2017 188
Figure 65: Promotional spend for Lialda split by type of promotion for US and the UK, 2007 193
Figure 66: Lialda (MMX mesalazine) sales for inflammatory bowel disease in the US and 5EU ($m), 2007-2017 195
Figure 67: Lialda (MMX mesalazine) sales for ulcerative colitis and Crohn's disease in the US and 5EU ($m), 2007-2017 196
Figure 68: Golimumab (CNTO-148) sales in ulcerative colitis in the US and 5EU, split by country ($m), 2007-2017 203
Figure 69: Salofalk Granustix sales in inflammatory bowel in the seven major markets ($m) , 2007-2017 206
Figure 70: Entocort (budesonide) sales in inflammatory bowel disease in the US ($m), 2007-2017 208
Figure 71: Colazal (balsalazide) sales in inflammatory bowel disease in the US ($m), 2007-2017 210
Figure 72: CCX-282 sales for inflammatory bowel disease in the seven major markets ($m) , 2007-2017 214
Figure 73: Ustekinumab (CNTO-1275) sales for Crohn's disease in the US ($m), 2007-2017 216
Figure 74: MMX budesonide sales for ulcerative colitis in the US and 5EU ($m), 2007-2017 218
Figure 75: Centocor's inflammatory bowel disease portfolio sales across the seven major markets ($m), 2007-2017 226
Figure 76: Brand erosion of Rowasa (mesalazine) following first generic entrant in the US 244
